What is Inflammatix?
Inflammatix is at the forefront of molecular diagnostics, developing proprietary tests that interpret the human immune system to deliver swift and accurate results. The company's technology leverages advanced machine learning and unique biomarkers to aid physicians in the rapid diagnosis and treatment of acute infections and sepsis. By providing timely insights, Inflammatix aims to optimize patient care pathways, reduce healthcare costs, and mitigate the impact of severe public health threats. Their focus on the immune response offers a novel paradigm in diagnostic science.
How much funding has Inflammatix raised?
Inflammatix has raised a total of $216.5M across 6 funding rounds:
Other Financing Round
$6M
Series C
$32M
Grant
$7.4M
Series D
$102M
Grant
$12.1M
Series E
$57M
Other Financing Round (2019): $6M with participation from Biomedical Advanced Research and Development Authority (BARDA)
Series C (2020): $32M led by Think.Health Ventures, Grey Sky Venture Partners, Northpond Ventures, and Khosla Ventures Acquisition
Grant (2020): $7.4M supported by Biomedical Advanced Research and Development Authority
Series D (2021): $102M featuring Think.Health, OSF Healthcare Ventures, Northpond Ventures, Khosla Ventures Acquisition, and D1 Capital Partners
Grant (2021): $12.1M backed by Biomedical Advanced Research and Development Authority (BARDA
Series E (2024): $57M with participation from D1 Capital Partners Master, Think.Health Ventures, Khosla Ventures, Northpond Ventures, and Iberis Capital
Key Investors in Inflammatix
D1 Capital Partners Master
D1 Capital Partners Master LP is a venture capital firm that operates in the Venture Capital & Private Equity industry, headquartered in New York, New York.
Think.Health Ventures
Think.Health Ventures is a company operating in the Information & Document Management industry, focused on venture investments.
Northpond Ventures
Northpond Ventures is dedicated to advancing science and technology to create significant impacts on humanity, focusing on breakthrough innovations and entrepreneurial ventures.
What's next for Inflammatix?
The recent major strategic investment positions Inflammatix for accelerated growth and expanded market penetration. With substantial enterprise-level backing, the company is poised to scale its operations, further develop its diagnostic platforms, and broaden its clinical applications. This infusion of capital will likely fuel research and development initiatives, enhance commercialization efforts, and strengthen strategic partnerships. Inflammatix's trajectory suggests a continued focus on innovation within the diagnostics sector, aiming to solidify its leadership in immune-based testing for critical care.
See full Inflammatix company page
